After the investigator leaves
At the close of many FDA inspections, the investigator issues a Form 483 listing conditions that may violate the rules the agency enforces. The observations are not a final agency finding, yet they become part of the record, and the company's written response is often read closely when the agency decides whether to escalate. Escalation can range from a warning letter to import restrictions for a foreign site or, in serious cases, court action brought through the Department of Justice. Responses that arrive promptly are more likely to be considered before the agency settles on next steps, so root-cause work and drafting usually begin the same week. Life sciences regulatory matters of this kind are rarely only legal or only technical, and the strongest responses tend to come from both teams working on one document.
Getting the facts and the record straight
Before anyone writes a response, it helps to know exactly what was observed, which documents the investigator reviewed or copied, and what employees said during interviews. Collect the notes your own team kept during the inspection, the batch or device history records at issue, and any earlier observations or audit findings that touch the same systems. Commitments in a response should be ones the company can actually meet on the dates it gives, because the agency tends to check them at the next visit. Avoid creating new documents that recast old events, and route internal analyses through counsel where privilege may matter. If complaint files or adverse event reports are involved, confirm that any required reports to the agency were made.
Choosing the next move
Not every observation calls for the same treatment. Some can be resolved with a corrective action and evidence that it worked, while others raise the harder question of whether a product already on the market needs a field correction or a recall. We review the 483 or the letter, the timing of any response, and how the issue might affect pending applications, customer contracts, or public disclosures if the company is publicly traded. We also consider whether a meeting with the agency would help and who should attend it. The company then decides how to sequence remediation and communication, with a clear view of what each choice signals to regulators.
